- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05959850
A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS (AMBALS)
September 4, 2023 updated by: The Florey Institute of Neuroscience and Mental Health
AMBroxol Therapy for ALS (AMBALS) Trial: a Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trial of Ambroxol for ALS
Ambroxol is a simple cough medicine that is predicted to slow ALS disease progression.
This study aims to investigate if ambroxol in high doses is effective in treating ALS.
This study will be carried out across 5 research sites in Australia (2 NSW, 1 VIC, 1 SA and 1 TAS), where newly diagnosed ALS patients will be asked to participate.
Participation will be over a 32-week period, where they will come in for a 4-week screening, 24-week treatment, and 4-week end of study safety follow-up period.
The participants will receive either the placebo or drug solution that they will take three times a day, up-dosing each week until they reach the maximum dose or highest dose they can tolerate.
Throughout the study their disease progression will be assessed using tests, questionnaires, and blood biomarkers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a double-blind, randomised, placebo-controlled phase 2 clinical trial, to assess the safety, tolerability and efficacy of ambroxol therapy in ALS patients by using electrophysiological and functional measures to detect preservation of motor units.
The study design will have participants be randomised to either ambroxol or placebo at a 2:1 ratio (ambroxol (n=34) and placebo (n=16)).
Participants randomised to the active arm will receive various doses of ambroxol in solution, taken orally, three times a day.
Doses will be increased pending a safety review for each participant.
The doses will be 180mg per day, 260mg per day, 540mg per day, 900mg per day, and 1260 mg per day.
Each week safety bloods will be performed to assess tolerance to the dose.
Participants randomised to the control arm will receive a placebo for the duration of the study.
Disease progression will be assessed by the following, time to event (death, need for tracheostomy, the need for gastrostomy feeding or non-invasive ventilation support (≥12 hours a day in a 24-hour period), or ≥6-point progression (ALS functional rating score-revised).
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bradley Turner
- Phone Number: +61 3 9035 6521
- Email: bradley.turner@florey.edu.au
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2139
- Recruiting
- Concord Repatriation General Hospital
-
Contact:
- Julie Ryder
- Phone Number: +61 2 9767 8475
- Email: julie.ryder@health.nsw.gov.au
-
Principal Investigator:
- Steve Vucic
-
Sydney, New South Wales, Australia, 2050
- Recruiting
- Brain and Mind Centre
-
Contact:
- Eleanor Ramsey
- Phone Number: +61 2 9114 4258
- Email: eleanor.ramsey@sydney.edu.au
-
Principal Investigator:
- Matthew Kiernan
-
-
South Australia
-
Adelaide, South Australia, Australia, 5042
- Recruiting
- Flinders Medical Centre
-
Principal Investigator:
- David Schultz
-
Contact:
- Edlira Dishnica
- Phone Number: +61 8 8204 5168
- Email: edlira.dishnica@sa.gov.au
-
-
Tasmania
-
Launceston, Tasmania, Australia, 7250
- Recruiting
- Launceston General Hospital
-
Contact:
- Lauren Giles
- Email: lauren.giles@ths.tas.gov.au
-
Principal Investigator:
- Lauren Giles
-
-
Victoria
-
Melbourne, Victoria, Australia, 3162
- Recruiting
- Calvary Health Care Bethlehem
-
Principal Investigator:
- Susan Mathers
-
Contact:
- Emma Windebank
- Phone Number: +61 3 9834 9430
- Email: Emma.Windebank@calvarycare.org.au
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Must have given written informed consent before any study related assessments are performed and must be able to understand purpose of the study, including any possible risks and adverse events.
- ALS as diagnosed according to the recently proposed Gold Coast diagnostic criteria.
- First symptom of ALS less than or equal to 18 months prior to screening. The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS.
- Forced vital capacity (FVC) greater than or equal to 60% of predicted value as adjusted for gender, height and age at the Screening Visit.
- Male or female patients aged 18 years or greater (inclusive) and less than 85 years at the time of ALS diagnosis.
- Able to swallow liquid.
- Able to perform reproducible pulmonary function tests
- Female patients must be post-menopausal or sterilized or must not be breastfeeding, have no intention to become pregnant during the study, and use acceptable methods of contraception or abstain from intercourse.
- Male patients who have not had a vasectomy and confirmed zero sperm count must agree after receiving the first dose of study drug either to use acceptable methods of contraception or abstain from intercourse.
- If on riluzole, stable dosing for 30-days prior to screening.
- Pre-study ALSFRS-R progression between disease onset and screening of greater than or equal to 0.5 points/month (calculated by ALSFRS-R total score decline from 48 divided by the months since onset of ALS symptoms).
Exclusion Criteria:
- Use of non-invasive ventilation (NIV) support for ALS only or gastrostomy tube at time of screening.
- Exposure to investigational drug within 12-weeks prior to screening.
- At screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or data.
- Patient with a history of significant other major medical conditions based on the Investigator's judgment.
- Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures.
- Any person who is an employee or an Investigator or Sponsor, or an immediate relative of an Investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Active
Ambroxol taken 3x daily.
Variation in doses as follow-up progresses.
For detailed information, see Intervention Description.
|
Participants in the study will receive varying doses of ambroxol in solution, 3 times per day.
Doses will be increased pending a safety review, up to a maximum of 1260mg/day.
Blood tests will be conducted weekly to assess tolerance.
Compliance will be monitored by returning used bottles.
The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits.
After the final follow-up, there will be an end of study safety visit occurring 4 weeks later.
The total time of participation will be 32 weeks.
This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits).
These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks.
Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
Other Names:
|
Placebo Comparator: Placebo Comparator: Control
Glucose Placebo, taken 3x daily.
Variation in doses as follow-up progresses.
For detailed information, see Intervention Description.
|
Participants randomised to the control arm will receive a placebo for the duration of the study.
The placebo will look and taste like ambroxol, but will have no active ingredient.
Participants will not be told which arm they have been randomised to.
The placebo will primarily be a glucose solution, however it will also have flavouring (e.g.
bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to event
Time Frame: Time to event for a maximum of 24 weeks from baseline
|
Time to event (death, need for tracheostomy, the need for gastrostomy feeding or non-invasive ventilation (NIV) support (greater than or equal to 12 hours a day in a 24-hour period), or greater than or equal to 6-point progression on the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)) This will be measured by patient medical records, and the completion of the ALSFRS by investigators.
|
Time to event for a maximum of 24 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALS functional rating score-revised (ALSFRS-R)
Time Frame: 24 weeks from Baseline
|
Change in ALSFRS-R Score
|
24 weeks from Baseline
|
Motor unit number estimation (MUNIX)
Time Frame: 24 weeks from Baseline
|
Change in MUNIX values
|
24 weeks from Baseline
|
Split Hand Index (SI)
Time Frame: 24 weeks from Baseline
|
Change in SI value
|
24 weeks from Baseline
|
Neurophysiology Index (NPI)
Time Frame: 24 weeks from Baseline
|
Change in NPI Value
|
24 weeks from Baseline
|
Kings staging system
Time Frame: 24 weeks from Baseline
|
Change in Kings stage
|
24 weeks from Baseline
|
Respiratory function (FVC) as measure by a Spirometer
Time Frame: 24 weeks from Baseline
|
Change in FVC
|
24 weeks from Baseline
|
Survival
Time Frame: 24 weeks from Baseline
|
Overall survival rate
|
24 weeks from Baseline
|
Serum NFL levels
Time Frame: 24 weeks from Baseline
|
Change in Serum NFL Levels
|
24 weeks from Baseline
|
Assessment of Quality of Life (AQoL)
Time Frame: 24 weeks from Baseline
|
Change in AQoL score
|
24 weeks from Baseline
|
Muscle strength assessment as measured by the Medical Research Council (MRC) Scale for Muscle Strength
Time Frame: 24 weeks from Baseline
|
Change in Muscle strength, where Grade 0 is no visible contraction and Grade 5 is Normal
|
24 weeks from Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Bradley Turner, The Florey Institute of Neuroscience and Mental Health
- Principal Investigator: Steve Vucic, Concord Repatriation General Hospital
- Principal Investigator: Matthew Kiernan, Brain and Mind Centre (The University of Sydney)
- Principal Investigator: Susan Mathers, Calvary Health Care Bethlehem
- Principal Investigator: David Schultz, Flinders Medical Centre
- Principal Investigator: Lauren Giles, Launceston General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
July 17, 2023
First Submitted That Met QC Criteria
July 17, 2023
First Posted (Actual)
July 25, 2023
Study Record Updates
Last Update Posted (Actual)
September 7, 2023
Last Update Submitted That Met QC Criteria
September 4, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLO-AMB-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan to have individual participant data available to other researchers
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Ambroxol
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Agyany Pharma LTDRecruiting
-
Lawson Health Research InstituteNot yet recruiting
-
Shaare Zedek Medical CenterCompletedGaucher Disease, Type 1Israel
-
SanofiCompletedPharyngitisSouth Africa
-
Boehringer IngelheimCompleted